Aktie ARGOS THERAPEUTICS INC
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Argos Therapeutics Inc Nasdaq

Aktien

US0402211033

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Argos Therapeutics, Inc. Went Out of Business
First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.
First Amended Liquidation Plan Filed by Argos Therapeutics, Inc.
Revised Disclosure Statement Approved on Interim Basis for Argos Therapeutics, Inc.
Liquidation Plan and Disclosure Statement Filed by Argos Therapeutics, Inc.
Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.
Motion for Asset Sale Approved for Argos Therapeutics, Inc.
Notice of Successful Bidder Filed by Argos Therapeutics, Inc.
Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.
CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..
Bidding Procedure Approved for Argos Therapeutics, Inc.
Argos Therapeutics, Inc. will Change its Ticker to ARGSQ from ARGS
Argos Therapeutics, Inc. Announces Management Changes
Argos Therapeutics, Inc. Filed for Bankruptcy
Motion for Asset Sale Filed by Argos Therapeutics, Inc.
CELLSCRIPT, LLC and Cell Therapies, LLC entered into an asset purchase agreement to acquire Substantially All of the Non-Cash Assets of Argos Therapeutics, Inc. for approximately $1.7 million.
Argos Therapeutics, Inc.(NasdaqCM:ARGS) dropped from S&P TMI Index
Argos Therapeutics, Inc. Announces Resignation of Sander van Deventer as Board of Directors
Argos Therapeutics, Inc.(NasdaqCM:ARGS) dropped from NASDAQ Composite Index
Argos Therapeutics, Inc. announced that it has received $0.45 million in funding from Lummy (Hong Kong) Co., Ltd.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2G8YQ Aktie
  4. Aktie
  5. Nachrichten Argos Therapeutics Inc
  6. Andere Sprachen